Who ever heard of 16p11.2 deletion syndrome? Parents’ perspectives on a susceptibility copy number variation syndrome

被引:0
作者
Lotte Kleinendorst
Lieke M. van den Heuvel
Lidewij Henneman
Mieke M. van Haelst
机构
[1] Amsterdam UMC,Department of Clinical Genetics
[2] University of Amsterdam,Department of Clinical Genetics and Amsterdam Reproduction & Development research institute
[3] Amsterdam UMC,undefined
[4] Vrije Universiteit Amsterdam,undefined
来源
European Journal of Human Genetics | 2020年 / 28卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Chromosomal microarray analysis is an important diagnostic tool to identify copy number variations (CNV). Some of the CNVs affect susceptibility regions, which means that deletions or duplications in these regions have partial penetrance and often give an increased risk for a spectrum of neurocognitive disorders. Not much is known about the impact of rare CNV susceptibility syndromes on the life of patients or their parents. In this study, we focus on one specific susceptibility CNV disorder, 16p11.2 deletion syndrome. This rare condition is characterised by an increased risk of mild intellectual disability, autism spectrum disorder, epilepsy, and obesity. We aimed to explore the impact of such a disorder on the family members involved in the daily care of children with this syndrome. Three focus group discussions were held with 23 Dutch (grand)parents. Thematic analysis was performed by two independent researchers. The following five themes emerged: (1) the end of a diagnostic odyssey and response to the diagnosis, (2) after the diagnosis—life with a child with 16p11.2 deletion syndrome, (3) access to medical care and support services, (4) nobody knows what 16p11.2 deletion syndrome is, and (5) future perspective—ideal care. The participants experienced a lack of knowledge among involved professionals. Together with the large variability of the syndrome, this led to fragmented care and unfulfilled needs regarding healthcare, social, and/or educational assistance. Care for children with a CNV susceptibility syndrome could be improved by a multidisciplinary approach or central healthcare professional, providing education and information for all involved professionals.
引用
收藏
页码:1196 / 1204
页数:8
相关论文
共 82 条
[1]  
Miller DT(2010)Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies Am J Hum Genet 86 749-64
[2]  
Adam MP(2016)Communicating microarray results of uncertain clinical significance in consultation summary letters and implications for practice Eur J Hum Genet 25 22-30
[3]  
Aradhya S(2011)An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities Genet Med. 13 777-84
[4]  
Biesecker LG(2018)The psychosocial impact of 22q11 deletion syndrome on patients and families: a systematic review Am J Med Genet A 176 2215-25
[5]  
Brothman AR(2012)22q11.2 deletion syndrome: attitudes towards disclosing the risk of psychiatric illness J Genet Couns 21 825-34
[6]  
Carter NP(2013)Copy number variation: what is it and what has it told us about child psychiatric disorders? J Am Acad Child Adolesc Psychiatry 52 772-4
[7]  
Paul JL(2009)Extending the phenotype of recurrent rearrangements of 16p11.2: deletions in mentally retarded patients without autism and in normal individuals Eur J Med Genet 52 77-87
[8]  
Pope-Couston R(2014)CNVs conferring risk of autism or schizophrenia affect cognition in controls Nature 505 361-6
[9]  
Wake S(2008)Association between microdeletion and microduplication at 16p11.2 and autism N Engl J Med 358 667-75
[10]  
Burgess T(2018)Deep phenotyping of speech and language skills in individuals with 16p11.2 deletion Eur J Hum Genet 26 676-86